罗格列酮对腹膜透析患者微炎症反应状态的影响

Effects of rosiglitazone on inflammation in peritoneal dialysis patients

目的:探讨罗格列酮治疗对腹膜透析患者微炎症状态的影响。方法:收集持续性腹膜透析患者50例,治疗组患者给予罗格列酮4 mg·d-1,对照组常规腹膜透析治疗,两组均治疗12周观察指标变化。两组患者治疗前后测定空腹血糖(FBG)、糖化血红蛋白(HbA1c)、血红蛋白(Hb)、血清总胆固醇(TC)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)和三酰甘油(TG)、高敏C反应蛋白(hs-CRP),采用ELISA方法进行检测肿瘤坏死因子α(TNF-α)和白介素6(IL-6)。采用HOMA-IR模型公式计算胰岛素抵抗指数(HOMA-IR)。结果:经过罗格列酮治疗12周后,患者FPG、HOMA-IR、hs-CRP、TNF-α、IL-6水平均有明显下降,并且与对照组比较具有显著统计学意义(P<0.05,P<0.01);HDL-C水平有明显升高,与对照组比较差异具有显著意义(P<0.05)。结论:罗格列酮可改善腹膜透析患者微炎症反应状态及胰岛素抵抗,纠正脂代谢紊乱。

OBJECTIVE To assess the effects of rosiglitazone on inflammation in peritoneal dialysis patients.METHODS Fifty continuous ambulatory peritoneal dialysis patients were collected in our hospital.The treatment group was assigned to receive rosiglitazone 4 mg once daily and control group received regular peritoneal dialysis for 12 weeks.Some serum examinations which included fasting blood glucose（FBG）,glycosylated hemoglobin A1c（HbA1c）,haemoglobin（Hb）,serum total cholesterol（TC）,high density lipoprotein cholesterol（HDL-C）,low density lipoprotein cholesterol（LDL-C）,triglycerides（TG） and high sensitivity C reactive protein（hsCRP） were measured,tumor necrosis factorα（TNF-α） and interleukin-6（IL-6） levels were measured by ELISA,and homeostasis model assessment of insulin resistance（HOMA-IR） were evaluated before and after treatment.RESULTS After 12 weeks treatment of rosiglitazone,the levels of FPG、HOMA-IR、hs-CRP、TNF-α、IL-6 declined significantly（P〈0.05,P〈0.01）;the level of HDL-C raised significantly（P〈0.05）.CONCLUSION There are significant anti-inflammatory effect,improving insulin resistance and antilipidemic effect of rosiglitazone in peritoneal dialysis patients.